April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Clinical Experience with Ahmed M4 Tube-Shunt in Various Types of Glaucoma: A Pilot Study
Author Affiliations & Notes
  • Timothy Sullivan
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Victor Cvintal
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Wanda Deborah Hu
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Feyzahan Ekici
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Naryan Sabherwal
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Michael Waisbourd
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Michael J Pro
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Marlene R Moster
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Footnotes
    Commercial Relationships Timothy Sullivan, None; Victor Cvintal, None; Wanda Hu, None; Feyzahan Ekici, None; Naryan Sabherwal, None; Michael Waisbourd, None; Michael Pro, None; Marlene Moster, Aeon Astron (F), Aerie Pharmaceuticals (F), Alcon Laboratories, Inc. (C), Alcon Laboratories, Inc. (R), Allergan, Inc. (C), Allergan, Inc. (R), BD Medical -Ophthalmic Systems (C), Genentech (F), Merck (C), Merck (R), New World Medical (F), Solex (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6133. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Timothy Sullivan, Victor Cvintal, Wanda Deborah Hu, Feyzahan Ekici, Naryan Sabherwal, Michael Waisbourd, Michael J Pro, Marlene R Moster; Clinical Experience with Ahmed M4 Tube-Shunt in Various Types of Glaucoma: A Pilot Study. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6133.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the safety and efficacy of the Ahmed Glaucoma Valve model M4 (AGV; New World Medical Inc., Rancho Cucamonga, CA). This device consists of a porous polythethiene shell, which was designed to reduce the fibrotic reaction around the plate. 1

 
Methods
 

Patients’ charts who underwent implantation of the AGV model M4 from 12/1/12 to 8/31/13 were reviewed. Primary outcome: intraocular pressure (IOP) reduction; Secondary outcome: number of glaucoma medications and number of reoperations related to surgical complications or glaucoma. Clinical parameters were collected pre-operatively and on day 1, week 1 and 1-, 3- and 6- months post-operatively.

 
Results
 

Thirty-six eyes were included. Mean follow-up time was 136 ± 62 days. Preoperatively, subjects had a mean of 0.97 ± 1.0 prior glaucoma surgeries and a mean LogMAR visual acuity of 1.04 ± 0.89. Table 1 shows the mean IOP and number of glaucoma medications by pre- and post-operative visit. The percentage of IOP drop in day 1 and 3 month was 72% and 22% respectively. The average use of medications per patient was 2.9 ± 0.84 and 0.13 ± 0.43 before surgery and 3 months after, respectively. Thirty six percent of the patients had at least 1 complication; hyphema and shallow anterior chamber were the most prevalent early complications. Ten eyes underwent additional procedures to manage surgical complications. Four eyes needed reoperation for glaucoma 3 months post-operatively. No significant vision-threatening complications were recorded.

 
Conclusions
 

The AGV model M4 effectively reduced IOP during the first post-operative month. The IOP reduction at 1-month is comparable to published data. There was a trend toward higher IOP values after 3- and 6- months; however, this can be explained by a lower number of hypotensive drops used, compared to the previous report. Further studies are required to evaluate the long-term efficacy and safety of this device.

  
Keywords: 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×